Novo Nordisk has received approval from the Drug Controller General of India to conduct phase-III studies for its new weekly insulin injection, IcoSema, in India. IcoSema is a combination of insulin and Semaglutide and is meant to control blood sugar levels in people with type-two diabetes. The proposed weekly insulin shot could be a game changer as it would decrease the discomfort of daily injections and may be as effective as regular insulin.

Related Keywords

Denmark , India , Danish , Anoop Misra , Ozempic Semaglutide , Centre Of Excellence , Novo Nordisk , Drug Administration , Drug Controller General , Metabolic Diseases , Icosema , Semaglutide , Us Food And Drug Administration , Icodec , Drug Controller General Of India ,